Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) 34% HIGHER; announced that its Phase 3 EASE LID clinical trial evaluating the companys investigational ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Special Reports

Adamas Pharma (ADMS) Sees Red-to-Green MoveDecember 24, 2015 11:28 AM Cowen Upgrades Rovi Corp. (ROVI) to OutperformDecember 24, 2015 8:31 AM Piper Jaffray Reiterates Overweight on Rovi Corp. (ROVI) Following AT&T/DTV License Agreement December 24, 2015 7:07 AM Brean Capital Believes Visibility on Nike (NKE) Remains High; Raises Price Target to $147 December 24, 2015 6:42 AM Adamas Pharma (ADMS) Ramps Into the CloseDecember 23, 2015 3:38 PM Brean Capital Raised Price Target on Nike (NKE) Following 2Q EPS Beat December 23, 2015 9:58 AM